Clinical Trial Update: A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluated the safety and immunogenicity of heterologous prime-boost Ebola vaccine regimens in healthy participants. The study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Ad26.ZEBOV
• MVA-BN-Filo

Snippet

Sponsor: Crucell Holland BV | Conditions: Healthy | Phase 1 | Status: COMPLETED